Initial Results of a Phase I/II Study Evaluating the Maximum Tolerated Dose, Pharmacokinetics, Safety, and Efficacy of Hyperthermia and Lyso-thermosensitive Liposomal (LTSL) Doxorubicin in Patients with Breast Cancer Recurrence at the Chest Wall (RCW)